Bioprocessing White Papers

  1. Systematic Strategy To Reduce The Cost Of Goods Sold 3/26/2026

    Learn key ways to cut biologics manufacturing costs through smarter process design, material choices, and supply resilience — driving more efficient, reliable, and commercially sustainable production.

  2. Tool Enzymes For Antibody-Drug Conjugate Development And Manufacturing 3/26/2026

    See how modern tool enzymes enable cleaner, more consistent ADC conjugation, sharper analytics, and a smoother path from research to clinical development — practical guidance for manufacturing.

  3. Criteria For Effective Bioprocess Scale-Up 3/25/2026

    Discover four essential bioprocess scale-up criteria and how each balances hydrodynamics, shear, and mass transfer across manufacturing scales.

  4. Biocapacitance Measurement: A PAT Tool For Biomass Measurement In An Upstream Process 3/20/2026

    Leverage process analytical technologies (PAT) to gain real-time insight into product quality, strengthen control strategies, and build more efficient, scalable manufacturing processes for future success.

  5. A Cell Line Development Platform Accelerating Timelines To Clinic 3/20/2026

    To support a seamless transition from early clinical studies through to commercial manufacturing, cell line expression systems must be carefully designed and selected based on several critical attributes.

  6. Improvements In ADC Efficacy And Stability 3/17/2026

    Antibody–drug conjugates link antibodies to potent toxins, but increased hydrophobicity impairs stability, manufacturing, and PK, spurring interest in hydrophilic linker strategies.

  7. A Faster Path To Genomic Medicine Feasibility 3/17/2026

    Life Edit accelerates genomic medicine by comparing five editing modalities, engineering new enzymes, and rapidly pinpointing optimal strategies that boost feasibility, cut risk, and speed clinical progress.

  8. A Guide To Process Transparency In Custom Lab Automation Development 3/16/2026

    Discover a practical guide to building custom automation systems with clarity and confidence, as well as how transparent processes reduce risk, prevent misalignment, and support reliable testing.

  9. Tailoring Viral Clearance Study Design 3/4/2026

    Viral‑clearance studies need phase‑appropriate design, strong virus stocks, modality‑specific risk assessment, and alignment with evolving regulations for reliable safety outcomes.

  10. Key Selection Criteria For Cell & Gene Therapy CDMOs 3/4/2026

    Choosing the right CDMO requires early internal assessment plus strong technical capability, agility, advocacy, clear communication, and long‑term alignment to meet evolving cell and gene therapy needs.